An interventional study of Songling Xuemaikang Capsule and Songling Xuemaikang Capsule Placebo in Hypertension and Cerebral Small Vessel Diseases, sponsored by Dongzhimen Hospital, Beijing. Not yet recruiting at 1 site in China. Open to participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Dongzhimen Hospital, Beijing · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 410 studies in Hypertension with a site in China — 124 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.
Among the 410 studies in Hypertension with a site in China, this one is the 236th largest by planned enrollment of the 308 interventional ones that give a count, is one of 48 that started in 2025, is one of 146 with no phase, reaches primary completion later than 65 of the 147 other live ones, and was the 351st registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →124 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:
Shandong Suncadia Medicine Co., Ltd. · Sites in China
Ages 18–80
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
China Medical University, China · Sites in China
Ages 50–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 55 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
410 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 23 · Phase 3 50 · Phase 4 76
First in 1998; this study’s year is marked. 48 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 253 across the 308 interventional studies, 1,000 across the 102 observational. Of the 161 that completed or were terminated, 22 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
103 of 410 have an industry lead sponsor. The 10 most frequent:
Dongzhimen Hospital, Beijing is the lead sponsor of 45 studies on the registry; 19 are open to participants now.
Dongzhimen Hospital, Beijing has 1 study filed under Hypertension — fewer than ten, so there is no comparison to draw.
47 of the studies in Hypertension with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT06948422Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) | 2027-09 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
| NCT06952530Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 | 2027-09 |
| NCT07241338Jing LiuSacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity | 2026-11 |
Add all 47 to your calendar (.ics) → With an account.
Among the 410 studies in Hypertension with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebral small vessel disease (CSVD) is a common age-related microvascular disease related to the slow accumulation of damage to small arteries, veins, and capillaries. Hypertension is a risk factor for cerebrovascular disease, and its damage to the vascular endothelium is one of the key contributing factors to the pathogenesis of CSVD. CSVD has an insidious onset, and patients may exhibit no clinical symptoms in the early stage. Common clinical manifestations of chronic CSVD include vascular dementia, depression, gait disturbance, and abnormalities in swallowing and urinary functions. There is currently no specific treatment for CSVD.
Existing studies have shown that Songling Xuemaikang capsule (SXC) combined with antihypertensive drugs exerted significant effects on systolic blood pressure (SBP), diastolic blood pressure (DBP), 24-hour SBP, and 24-hour DBP, while also improving symptoms of hypertension. Animal experiments have demonstrated that SXC can reduce apoptosis and alleviate cerebral ischemia-reperfusion injury, exerting neuroprotective effects. Additionally, a previously completed multicenter, randomized, double-blind, non-inferiority-designed clinical trial by the team, conducted in patients with primary hypertension, showed that SXC were non-inferior to losartan potassium in reducing diastolic blood pressure. Therefore, exploring the therapeutic potential of SXC in CSVD is highly necessary.
This project is a randomized, double-blind, placebo-controlled multicenter clinical study to investigate the clinical efficacy and safety of SXC in the treatment of hypertension with CSVD. A total of 90 subjects who met the subject screening criteria are planned to be enrolled, with 45 patients in the test group and 45 patients in the placebo group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Songling Xuemaikang Capsule, 3 capsules/time, tid, p.o
Drug: Songling Xuemaikang Capsule
Songling Xuemaikang Capsule placebo, 3 capsules/time, tid, p.o
Drug: Songling Xuemaikang Capsule Placebo
3 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
3 capsules/time, tid, p.o Duration of Treatment: 1 year (12 months)
Changes in the volume of white matter hyperintensities at 1 year.
Measure changes in the volume of white matter hyperintensities on brain MRI
Time frame: 1 year
Change from baseline in Mini-Mental State Examination (MMSE) at 1 year;
Change from baseline in Mini-Mental State Examination (MMSE). Score range is 0-30. Higher score means good cognition.
Time frame: 1 year
Change from baseline in Hamilton Anxiety Scale (HAMA) at 1 year;
Change from baseline in Hamilton Anxiety Scale (HAMA).Score range is 0-56. Higher score means a more severe state of anxiety.
Time frame: 1 year
Change from baseline in Hamilton Depression Scale (HAMD) at 1 year;
Change from baseline in Hamilton Depression Scale (HAMD). Score range is 0-76. Higher score means a more severe state of anxiety.
Time frame: 1 year
Change from baseline in Pittsburgh Sleep Quality Index (PSQI) at 1 year;
Change from baseline in Pittsburgh Sleep Quality Index (PSQI) at 1 year. Score range is 0-21. Higher score means worse sleep quality.
Time frame: 1 year
Change from baseline in Barthel Index (BI) at 1 year;
Change from baseline in Barthel Index (BI). Score range is 0-100. Higher score means good physical activities of daily living.
Time frame: 1 year
Feasibility of recruitment and retention
The feasibility is defined as \>95% of randomized patients retained at 1 year
Time frame: 1 year
Change from baseline in the symptom of hyperactivity of liver yang pattern at 1 year;
Change from baseline in the symptom of hyperactivity of liver yang pattern, which are headache, dizziness or vertigo, irritability, flushed face, red eyes, and yellow tongue coating. The study plans to analyze whether there are statistically significant differences in the incidence of the above six symptoms before and after treatment. On the other hand, for headache, dizziness or vertigo, irritability, if they do not resolve at follow-up time points, patient-reported outcomes (PROs) will be used to record the degree of change in patients' symptoms from baseline (expressed as a percentage, with \>100% indicating symptom worsening and \<100% indicating symptom relief), and statistical analysis will be carried out. For flushed face, red eyes, and yellow tongue coating, binary analysis will be performed based solely on their presence or absence.
Time frame: 1 year
Change from baseline in the mean 24h systolic blood pressure at 1 year;
Change from baseline in the mean 24h systolic blood pressure
Time frame: 1 year
Change from baseline in the mean 24h diastolic blood pressure at 1 year;
Change from baseline in the mean 24h diastolic blood pressure
Time frame: 1 year
Change from baseline in the mean daytime systolic blood pressure at 1 year;
Change from baseline in the mean daytime systolic blood pressure
Time frame: 1 year
Change from baseline in the mean daytime diastolic blood pressure at 1 year;
Change from baseline in the mean daytime diastolic blood pressure
Time frame: 1 year
Change from baseline in the mean nighttime systolic blood pressure at 1 year
Change from baseline in the mean nighttime systolic blood pressure
Time frame: 1 year
Change from baseline in the mean nighttime diastolic blood pressure at 1 year
Change from baseline in the mean nighttime diastolic blood pressure
Time frame: 1 year
Change from baseline in the mean 24h pulse pressure at 1year
Change from baseline in the mean 24h pulse pressure
Time frame: 1 year
Change from baseline in the blood pressure load at 1 year
Change from baseline in the blood pressure load
Time frame: 1 year
Change from baseline in the official systolic blood pressure at 1 year
Change from baseline in the official systolic blood pressure
Time frame: 1 year
Change from baseline in the official diastolic blood pressure at 1 year
Change from baseline in the official diastolic blood pressure
Time frame: 1 year
Change from baseline in the official pulse pressure at 1year
Change from baseline in the official pulse pressure
Time frame: 1 year
Change from baseline in the official blood pressure compliance rate at 1 year
Change from baseline in the official blood pressure compliance rate
Time frame: 1 year
Numbers in new vascular events from baseline to 1 year
New vascular events include ischemic stroke, TIA, cerebral hemorrhage, MI, pulmonary embolism, thrombosis, peripheral arterial occlusion
Time frame: 1 year
Numbers in all-cause hospitalization from baseline to 1 year
Numbers in all-cause hospitalization
Time frame: 1 year
Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Songling xuemaikang
Dongzhimen Hospital, Beijing